|August 25, At 2pm, 2022||Invitation to presentation of Acarix´s second quarter report|
|May 10, 2022||Naventus Corporate Finance & Partners, Healthcare Summit|
|March 16, 2022||Redeye Theme: Artificial Intelligence Seminar 2022|
|Feb 18, 2022||Capital Markets Day 2022: Acarix|
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.
The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹
Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).
Please visit our contact page to get in touch.
- US user manual v.12.5, prevalence 10,7%, algorithm version US3.2